



April 5, 2011

## **MannKind Posters Win Awards from International Pharmaceutical Aerosol Consortium on Regulation and Science**

DANBURY, Conn., Apr 05, 2011 (BUSINESS WIRE) -- **MannKind Corporation (Nasdaq: MNKD)** today announced that it was awarded two poster awards at the 2011 conference of the International Pharmaceutical Aerosol Consortium on Regulation and Science (IPAC-RS), held March 29-31 in Rockville, Maryland. IPAC-RS is an international association of companies that develop, manufacture or market orally inhaled and nasal drug products for local and systemic treatment of a variety of debilitating diseases such as asthma, chronic obstructive pulmonary disease and diabetes.

IPAC-RS awarded first place to a poster entitled, "Considerations for Human Factors in Developing a Pulmonary Drug/Device Delivery System" by Spencer Kinsey and Chad Smutney of MannKind Corporation. This poster described, among other things, the usability studies that were conducted on MannKind's next-generation inhaler system including simulated use through anatomical and physiological modeling, subject's experience during clinical use, and various design evaluations from the intended patient population.

IPAC-RS awarded third place to a poster entitled, "Pressure Profiling in Development of a Dry Powder Delivery System" by Chad Smutney, Benoit Adamo and Brendan Laurenzi of MannKind Corporation and John Polidoro and Carl Sahi of aVisionary Company (Manchester, Connecticut). This poster described wireless, electro-acoustic technology called BluHale<sup>®</sup> that MannKind developed to measure the inhalation effort created by users of its next-generation inhaler. The BluHale electronics are housed within a jacket that is easily affixed onto an inhaler. Pressure-time profiles are captured and transmitted wirelessly in real time to a graphical user interface. Use of this technology allows for data collection during dose administration without effect to sensor integrity or change to the airflow through the inhaler. BluHale has been used in the clinic to probe the impact of inhalation efforts on systemic exposures of Technosphere<sup>®</sup> inhalation powders, such as AFREZZA<sup>®</sup>. The graphical user interface helps to train subjects to achieve the prescribed inhalation effort parameters.

More information about MannKind's dry-powder inhalers and BluHale inhalation-profiling system is available at [www.mannkindcorp.com](http://www.mannkindcorp.com).

### **About MannKind Corporation**

MannKind Corporation (Nasdaq: MNKD) focuses on the discovery, development and commercialization of therapeutic products for patients with diseases such as diabetes and cancer. Its lead product candidate, AFREZZA<sup>®</sup>, is in late stage clinical investigation for the treatment of adults with type 1 or type 2 diabetes for the control of hyperglycemia. MannKind is also evaluating an investigational cancer immunotherapy product, MKC1106-MT, in a phase 2 clinical trial. MannKind maintains a website at [www.mannkindcorp.com](http://www.mannkindcorp.com) to which MannKind regularly posts copies of its press releases as well as additional information about MannKind. Interested persons can subscribe on the MannKind website to e-mail alerts that are sent automatically when MannKind issues press releases, files its reports with the Securities and Exchange Commission or posts certain other information to the website.

SOURCE: MannKind Corporation

MannKind Corporation  
Matthew Pfeffer, Chief Financial Officer  
661-775-5300  
[mpfeffer@mannkindcorp.com](mailto:mpfeffer@mannkindcorp.com)